Allogeneic stem-cell transplantation (SCT) is effective in part due to the graft-versus-tumor (GvT) potential of the donor graft~ however, successful SCT is often limited by graft-versus-host disease (GvHD). Acute GvHD is a major cause of morbidity and mortality after allogeneic SCT for blood cancers, occurring in 30-70% of transplants. With 28,000 allogeneic transplants performed worldwide each year, 15% of deaths following allogeneic SCT are a direct result of GvHD. Existing modalities for both prevention and treatment of GvHD are immunosuppressive, impair immune recovery and may limit the GvT effect. Our prior work has demonstrated that blockade of CCR5, a chemokine receptor, significantly decreased visceral GvHD in humans. The overarching goal of the current proposal is to exploit pharmacologic contro of lymphocyte trafficking after allogeneic SCT for therapeutic benefit. The central hypothesis is that T-cell trafficking plays a central role in the three major clinical and immunologic outcomes of allogeneic SCT - GvHD, GvT and reconstitution of a healthy immune system. To test this hypothesis, a clinical trial will be conducted in order to simultaneously investigate mechanistic and therapeutic endpoints. The experimental approach revolves around a phase II trial of extended CCR5 blockade in unrelated donor SCT for patients with blood cancers.
Aim 1 will determine the clinical and immunologic effects of extended CCR5 blockade after allogeneic SCT and identify predictors of response using appropriate pharmacodynamic and genotypic methods.
Aim 2 will determine the effect of extended CCR5 blockade on immune recovery and anti-tumor immunity by conducting a series of validated assays.
Aim 3 will identify the role of CCR5 in determining the tissue-tropism of effector T-cells, using a novel sequencing technology to survey the entire repertoire of T-cells and characterize their phenotype. The use of samples from 2 clinical trials together with control samples from a biospecimen bank will add power to the analysis of all 3 aims. This proposal is highly translational, revolves around a human clinical trial, and takes advantage of appropriate immune pharmacodynamic methods, developed specifically for this proposal, and genomic sequencing of T-cell clones to identif the chemokine receptor signature that is involved in T-cell recruitment into specific tissues. Combining patient-oriented research with state of the art immunologic assays will have a dual role - fuel our basic understanding of trafficking mechanisms in transplantation and cancer immunology, and at the same time change the standard of care by introducing a new class of targeted, minimally immunosuppressive medications to the field. If successful, this proposal may lead to a paradigm shift in the prevention of GvHD, setting the stge for a randomized clinical trial that will rely on the same clinical and immunologic endpoints to measure its success.
The aim of this proposal is to determine the role of lymphocyte chemotaxis in determining the outcomes of allogeneic stem-cell transplantation by studying the clinical and immunologic impact of CCR5 blockade as a proof of concept. The long-term goal is to develop effective ways to control lymphocyte recruitment in order to decrease the incidence of graft-versus-host disease, improve immune recovery and maintain effective anti- tumor immunity after stem-cell transplantation.
|Huffman, Austin P; Richman, Lee P; Crisalli, Lisa et al. (2017) Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant :|
|Huang, Qingrong; He, Shan; Tian, Yuanyuan et al. (2017) Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice. Blood 129:2737-2748|
|Moy, Ryan H; Huffman, Austin P; Richman, Lee P et al. (2017) Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood 129:906-916|
|Yam, Clinton; Crisalli, Lisa; Luger, Selina M et al. (2016) Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. Am J Hematol 91:883-7|
|Ganetsky, A; Shah, A; Miano, T A et al. (2016) Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplant 51:568-72|
|Meng, Lijun; Hu, Shaoyan; Wang, Jian et al. (2016) DLL4+ dendritic cells: Key regulators of Notch Signaling in effector T cell responses. Pharmacol Res 113:449-457|
|Luskin, Marlise R; Carroll, Martin; Lieberman, David et al. (2016) Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 22:1961-1967|
|Widman, Adam; Reshef, Ran (2016) Precision in donor selection: Identifying ideal stem-cell donors through their T cells. Exp Hematol 44:1020-1023|
|Mochizuki, Kazuhiro; Meng, Lijun; Mochizuki, Izumi et al. (2016) Programming of donor T cells using allogeneic ?-like ligand 4-positive dendritic cells to reduce GVHD in mice. Blood 127:3270-80|
|Meng, Lijun; Bai, Zhenjiang; He, Shan et al. (2016) The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation. J Immunol 196:1070-80|
Showing the most recent 10 out of 17 publications